SCHEMBL4166922

SCHEMBL4166922

CONC(=O)c1cc2c(C(=O)NCC(F)F)cn(Cc3ccc(F)cc3)c2cn1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MMP13 P45452 1/20 0.40
POLB P06746 1/20 0.39
PDE10A Q9Y233 1/20 0.39
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
THRB P10828 1/20 0.38
IDO1 P14902 1/20 0.38
FSCN1 Q16658 1/20 0.38
SERPINE1 P05121 1/20 0.38
KLKB1 P03952 1/20 0.37
MAPT P10636 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4163667 0.88 MEN1 (0.42) MEN1KMT2AMMP13POLBPDE10A
SCHEMBL1684180 0.86 MEN1 (0.40) MEN1KMT2AMMP13POLBPDE10A
SCHEMBL13778786 0.82 MMP13 (0.40) MEN1KMT2AMMP13PDE10AFSCN1
SCHEMBL13778782 0.82 KCNH2 (0.46) LMNA
SCHEMBL14542135 0.81 IKBKB (0.39) MEN1KMT2ALMNA
SCHEMBL13778783 0.81 DRD2 (0.47) MEN1KMT2A
SCHEMBL13778784 0.79 L3MBTL1 (0.47) POLBMAPT
SCHEMBL13778788 0.78 CNR1 (0.39) MEN1KMT2ATHRBFSCN1RXFP1
SCHEMBL4805963 0.78 MMP13 (0.41) MEN1KMT2AMMP13PDE4APDE4B
SCHEMBL1684248 0.78 HRH3 (0.44) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC 2009-07-02 US claimed
EP-1943249-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME Pfizer Products Incorporated (US) 2008-07-16 EP claimed
WO-2007039802-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER PRODUCTS INC. (US) 2007-04-12 WO claimed
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC 2009-07-02 US disclosed
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC 2009-07-02 US disclosed
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER INC 2009-07-02 US disclosed
EP-1943249-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME Pfizer Products Incorporated (US) 2008-07-16 EP disclosed
WO-2007039802-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER PRODUCTS INC. (US) 2007-04-12 WO disclosed
WO-2007039802-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME PFIZER PRODUCTS INC. (US) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170846-A1 INHIBITORS OF THE HIV INTEGRASE ENZYME IMPDH1, IMPA1, TYMP MEN1 4721/4885KMT2A 1368/4885MMP13 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.